Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherap...

Full description

Saved in:
Bibliographic Details
Published inTherapeutic Advances in Medical Oncology Vol. 15; p. 17588359231173177
Main Authors Petrillo, Angelica, Smyth, Elizabeth C., van Laarhoven, Hanneke W. M.
Format Book Review Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.01.2023
Sage Publications Ltd
SAGE Publishing
Subjects
Adenocarcinoma
Angiogenesis
Chemotherapy
ErbB-2 protein
Immunotherapy
Lymphocytes T
Metastases
Molecular modelling
Review
Claudin 18.2
SPEAR-T
trastuzumab deruxtecan
CAR-T cell
FGFR
target therapy
Online AccessGet full text

Cover

More Information
Summary:Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
These authors contributed equally
ISSN:1758-8359
1758-8340
1758-8359
DOI:10.1177/17588359231173177